Shirin Kalimuddin Profile
Shirin Kalimuddin

@shirinklmddn

Followers
677
Following
1K
Media
17
Statuses
489

Infectious Disease Physician & Researcher in Singapore | Emerging Infections & Clinical Trials | Tweets and opinions my own.

Singapore
Joined April 2021
Don't wanna be here? Send us removal request.
@shirinklmddn
Shirin Kalimuddin
9 months
Thank you TWIV @profvrr for discussing our paper which was recently published in @NatureMicrobiol - We showed that T cells were able to control viral infection independent of NAbs in humans @EngEongOoi @Anto_Berto @bertoletti_lab @dukenus @mysgh https://t.co/lW40CUZAMn
Tweet card summary image
nature.com
Nature Microbiology - The authors demonstrate the effectiveness of T cells in controlling acute viral infections, without neutralizing antibodies, by conducting an Orthoflavivirus vaccination and...
@profvrr
MicrobeTV
9 months
TWiV notes the HHS communication pause, describes research showing that rotavirus viroporin activity is necessary for intracellular calcium signals that contribute to viral pathogenesis, & more! 📺 https://t.co/alS2chfhK0
0
12
28
@shirinklmddn
Shirin Kalimuddin
2 months
Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study - The Lancet Infectious Diseases
Tweet card summary image
thelancet.com
TAK-003 was effective against symptomatic dengue and hospitalisation with dengue in adolescents during a large outbreak caused predominantly by dengue virus serotypes 1 and 2. These findings unders...
0
1
3
@YoujiaZhong
Youjia Zhong
3 months
The TV003 tetravalent live attenuated vaccine is finally in phase III trials in children! Excited to be part of it, and looking forward to the results 🤓
1
4
10
@dukenus
Duke-NUS Medical School
4 months
On 12 June, nearly 100 experts gathered at the "Challenging the Norm: Accelerating Dengue Countermeasures through Human Studies" symposium hosted by #DukeNUS scientists to push the boundaries of #dengue #research. Read more: https://t.co/R42U3U4rUl #DengueResearch #GlobalHealth
0
1
10
@ImperialMed
Imperial Medicine
6 months
Why do some people not get sick even when exposed to a virus? 🤒 Prof @p_openshaw explains how 'human challenge models' let us observe infection before symptoms start—a real-time map of the immune response in action. Read more in @EMJReviews 👇
Tweet card summary image
emjreviews.com
Peter Openshaw | Proconsul, Professor of Experimental Medicine, National Heart & Lung Institute - Faculty of Medicine, Imperial...
1
8
9
@SgSI_Immunology
SgSI
7 months
Registration for the SgSI’s 15th Annual Symposium 2025 is now open! 📅 29–30 May 2025 📍 LKCMed Auditorium @ NTU Novena, SG Explore the latest in: 🔹 Innate Immunity 🔹 Infectious Disease & more! 🌟 Top local & international speakers 🔗 Register now: https://t.co/bxxDURthjh
0
2
6
@shirinklmddn
Shirin Kalimuddin
7 months
Practice-changing SNAP RCT results presented at #ESCMIDGlobal this weekend. Proud that Singapore has been part of this global platform trial for Staph aureus bacteremia, with 3 sites including SGH @mysgh, TTSH & NUH.
@ABsteward
Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟
7 months
The most anticipated RCT in ID 🔥SNAP RCT🔥The largest RCT 2 date in SA bactermia N:1341 Cefazolin Vs ASPs ((flu)cloxacillin) for MSSA bacteremia Cefazolin is non-inferior (90d mortality)& less AKI than ASPs A practice-changer RCT that must change the guidelines #ESCMIDGlobal
2
6
11
@PaulSaxMD
Paul Sax
8 months
If someone thinks the measles outbreak and childhood death in Texas are "not unusual" or that these things "happen all the time", they are deeply misinformed. Don't be fooled.
Tweet card summary image
blogs.jwatch.org
My ID colleague Dr. Adam Ratner, Chief of Pediatric ID at NYU Medical Center, just published an insightful and remarkably timely book called Booster Shots:  The Urgent Lessons of Measles and the...
11
70
196
@ScienceMagazine
Science Magazine
9 months
Scientists have identified CD8+ T cells from human donors that can recognize naturally occurring influenza variants spanning more than 100 years, including the 1918 influenza A and 2024 H5N1. Learn more in @SciImmunology: https://t.co/3jURWDaOAT
7
63
194
@PaulSaxMD
Paul Sax
9 months
The communications pause for federal health agencies meant that the CDC couldn't publish MMWR last week -- first time in the publication's 60+ year history this has happened. Not happy☹️-- MMWR is a vital communication tool about infectious threats.
Tweet card summary image
blogs.jwatch.org
To us specialists in Infectious Diseases, there are certain verities we hold near and dear to our hearts: Antibiotics are miracle drugs, but the bugs will become resistant if we don’t use them...
4
44
124
@NatureMicrobiol
Nature Microbiology
10 months
OUT NOW – Vaccine-induced T cell responses control Orthoflavivirus challenge infection without neutralizing antibodies in humans By Shirin Kalimuddin, Eng Eong Ooi & colleagues @shirinklmddn @EngEongOoi https://t.co/QlNGiUHqYs
nature.com
Nature Microbiology - The authors demonstrate the effectiveness of T cells in controlling acute viral infections, without neutralizing antibodies, by conducting an Orthoflavivirus vaccination and...
0
6
17
@TheLancet
The Lancet
1 year
2024 is the worst year for dengue cases on record, with over 10 million cases already reported globally. Our latest Editorial highlights the need for a multipronged and multidisciplinary approach to halt the spread of dengue virus: https://t.co/g6EfvvyIdG
2
129
219
@chriskc_Lee
Christopher Lee
2 years
IN FOCUS: Is Southeast Asia losing the battle against dengue? With global warming, the no. of dengue infections are expected to ⬆️. Multiple strategies implemented in concert will be needed to address this increasing trend.
Tweet card summary image
channelnewsasia.com
Singapore, Malaysia and Indonesia have unleashed special mosquitoes injected with bacteria along with a slew of community efforts to tackle dengue. But with cases still on the rise, just how effect...
0
12
14
@shirinklmddn
Shirin Kalimuddin
2 years
Low-dose dengue virus 3 human challenge model: a phase 1 open-label study | Nature Microbiology
0
0
6
@shirinklmddn
Shirin Kalimuddin
2 years
Despite herculean efforts in vector control, dengue cases continue to surge. Vaccination would boost population immunity…unfortunately we still await licensing of Qdenga in Singapore (although already approved by EMA and several neighbouring countries).
straitstimes.com
Most of the patients who died of dengue in 2024 were elderly patients who are more vulnerable. Read more at straitstimes.com. Read more at straitstimes.com.
1
5
10
@bertoletti_lab
Bertoletti Lab
2 years
We are hiring!!! Interested in exploring the role of T cells in the control of viral infections and cancer? Join our team @dukenus in Singapore 🇸🇬! Apply here: 👉Postdoc: https://t.co/0twePDK4gg 👉Research Assistant (Local / PR only):
1
21
25
@TheLancetInfDis
The Lancet Infectious Diseases
2 years
New comment: Achieving zero deaths from dengue virus under evolving population immunity https://t.co/96Srm2J4uf
1
5
12
@shirinklmddn
Shirin Kalimuddin
2 years
In this perspective piece in ⁦@PLOSBiology⁩, ⁦we discuss the importance of integrating T cell immunity as a measure of vaccine efficacy, when developing future vaccines for pandemic preparedness. ⁦@EngEongOoi
journals.plos.org
In this Perspective, Eng Eong Ooi and colleagues argue that a failure to integrate T cell immunity as a determinant of vaccine efficacy could curtail the development of newer vaccines to help us...
1
11
26